MBS Digest

Reuters reports a new study urging closer monitoring of older adults on GLP-1 obesity drugs, especially for frailty signals such as malnutrition, dehydration, appetite loss, and muscle wasting. reuters.com/legal/litigati…

New July 13 data from Louisiana: metabolic/bariatric surgery in ages 10–25 was associated with 29–32% total weight loss over 1–5 years; 94% of those with follow-up had T2D remission. pbrc.edu/news/media/202…

Adolescent obesity needs more than “try harder.” A July 13 Louisiana study of 76 young patients found bariatric surgery produced 29–32% total weight loss over 1–5 years, with low 30-day complications. pbrc.edu/news/media/202…

AMA Morning Rounds highlights new Gallup data: 15% of U.S. adults report ever using GLP-1s for weight loss and 11% currently use them, while obesity prevalence fell from its 2022 peak. ama-assn.org/about/publicat…

New research suggests the metabolic benefits of bariatric surgery remain largely durable. Among 1,323 patients with initial comorbidity remission, recurrence was driven more by baseline disease severity than weight regain itself. link.springer.com/article/10.100…

What questions do you need to be asking during a new patient surgery consultation? mbs-digest.com/p/commentary-g…

A new economic analysis highlights the long-term cost-effectiveness of bariatric surgery for teens, demonstrating reduced comorbidities and supporting comprehensive obesity management strategies. luriechildrens.org/en/news-storie…

Obesity care infrastructure is lagging GLP-1 demand. AJMC reports coding gaps, payer restrictions, PA burden, and pharmacist billing limits are hampering multidisciplinary care models. ajmc.com/view/coding-co…

This week's Digest: Pointing you to the most impactful journal articles and news in the metabolic space mbs-digest.com/p/blade-vs-nee…

Obesity is not cosmetic risk. A new JAMA review summarized by KU Cancer Center ties obesity to cancer mechanisms and notes that ≥10% weight loss may be needed to meaningfully reduce risk. kucancercenter.org/news-room/news…

ADA 2026 coverage highlights a shift in obesity pharmacotherapy: beyond GLP-1 monotherapy toward multi-target approaches including triple agonists, amylin analogues and GLP-1/glucagon therapies. pharmacytimes.com/view/ada-2026-…

CMS posted pharmacy guidance for the Medicare GLP-1 Bridge, launching July 1 with a central processor for prior authorization, claims and pharmacy payment. cms.gov/medicare/cover…

Oral obesity meds are moving fast. AstraZeneca says elecoglipron hit Phase IIb endpoints and is moving to Phase III. More options are good, but access and long-term outcomes still matter. astrazeneca.com/media-centre/p…

New GLP-1 strategies matter, but so does the care model around them. A June 24 Northwestern report on pemvidutide points to weight loss plus lean-mass preservation—important if future trials confirm it. news.feinberg.northwestern.edu/2026/06/24/new…

ENDO 2026 study: adults with obesity starting GLP-1 therapy had fewer daily steps and less moderate-to-vigorous activity after initiation, underscoring the need for exercise support alongside medication. renalandurologynews.com/news/endo-sign…

Metabolic surgery vs GLP-1 medication is a tradeoff: about 0.5% early mortality, but 32% lower long term mortality, around 12 life years gained per 100 patients, and fewer CV and renal events. onlinelibrary.wiley.com/doi/epdf/10.10…

10 other search terms people use when searching about bariatric surgery mbs-digest.com/p/10-other-sea…

PBS NewsHour covered emerging observational data linking GLP-1 use with lower risk of some obesity-related cancers, while emphasizing the need for clinical trials. pbs.org/video/glp1-can…

ADA 2026 kept the obesity-drug pipeline in focus. Retatrutide phase 3 data showed very large weight loss and metabolic effects, but tolerability, patient selection, and long-term access will determine clinical use. adameetingnews.org/triple-hormone…